“Based upon current available information, coverage cannot be approved because there is insufficient scientific evidence to demonstrate the effectiveness of validity of whole genome sequencing for diagnostic purposes in the clinical setting.  At the present time, it is considered non-standard testing and falls under the category of experimental/investigational/unproven.  Your benefit plan does not cover experimental/investigational/unproven services.”